المؤلفون: Fontán-Vela, Mario, Kissling, Esther, Nicolay, Nathalie, Braeye, Toon, Van Evercooren, Izaak, Holm Hansen, Christian, Emborg, Hanne-Dorthe, Fabiani, Massimo, Mateo-Urdiales, Alberto, AlKerwi, Ala'a, Schmitz, Susanne, Castilla, Jesús, Martínez-Baz, Iván, de Gier, Brechje, Hahné, Susan, Meijerink, Hinta, Starrfelt, Jostein, Nunes, Baltazar, Caetano, Constantino, Derrough, Tarik, Nardone, Anthony, Monge Corella, Susana, VEBIS-Lot4 working group

مصطلحات موضوعية: COVID-19, SARS-CoV-2, Cohort design, Electronic health records, Hospitalisation, Multi-country study, Vaccine effectiveness, Humans, Aged, 80 and over, Retrospective Studies, Vaccine Efficacy, Europe, Hospitalization

الوصف: To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds. ; Sí

العلاقة: https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670Test; Euro Surveill. 2024 Jan;29(1):2300670.; http://hdl.handle.net/20.500.12105/18983Test; Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

الإتاحة: https://doi.org/20.500.12105/18983Test
https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670Test
https://hdl.handle.net/20.500.12105/18983Test

المؤلفون: Kislaya, Irina, Sentís, Alexis, Starrfelt, Jostein, Nunes, Baltazar, Martínez-Baz, Iván, Nielsen, Katrine Finderup, AlKerwi, Ala'a, Braeye, Toon, Fontán-Vela, Mario, Bacci, Sabrina, Meijerink, Hinta, Castilla, Jesús, Emborg, Hanne-Dorthe, Hansen, Christian Holm, Schmitz, Susanne, Van Evercooren, Izaak, Valenciano, Marta, Nardone, Anthony, Nicolay, Nathalie, Monge Corella, Susana, VEBIS-Lot4 working group

المساهمون: Unión Europea. European Centre for Disease Prevention and Control (ECDC)

مصطلحات موضوعية: COVID-19, COVID-19-related death, SARS-CoV-2, Cohort design, Hospitalization, Vaccine effectiveness, COVID-19 Vaccines, Humans, Aged, Vaccine Efficacy, Registries, Electronics

الوصف: Background: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making. ; European Centre for Disease Prevention and Control, Grant/Award Numbers: ECDC/2021/018, RS/2022/DTS/24104 ; Sí

العلاقة: https://doi.org/10.1111/irv.13195Test; Influenza Other Respir Viruses. 2023 Nov;17(11):e13195.; http://hdl.handle.net/20.500.12105/16894Test; Influenza and other respiratory viruses

الإتاحة: https://doi.org/20.500.12105/16894Test
https://doi.org/10.1111/irv.13195Test
https://hdl.handle.net/20.500.12105/16894Test

المؤلفون: Bonfiglio, Ferdinando, Zheng, Tenghao, Garcia-Etxebarria, Koldo, Hadizadeh, Fatemeh, Bujanda, Luis, Bresso, Francesca, Agreus, Lars, Andreasson, Anna, Dlugosz, Aldona, Lindberg, Greger, Schmidt, Peter T, Karling, Pontus, Ohlsson, Bodil, Simren, Magnus, Walter, Susanna, Nardone, Gerardo, Cuomo, Rosario, Usai-Satta, Paolo, Galeazzi, Francesca, Neri, Matteo, Portincasa, Piero, Bellini, Massimo, Barbara, Giovanni, Latiano, Anna, Hübenthal, Matthias, Thijs, Vincent, Netea, Mihai G, Jonkers, Daisy, Chang, Lin, Mayer, Emeran A, Wouters, Mira M, Boeckxstaens, Guy, Camilleri, Michael, Franke, Andre, Zhernakova, Alexandra, D'Amato, Mauro

المصدر: Gastroenterology. 155(1)

مصطلحات موضوعية: Genetics, Prevention, Digestive Diseases, Pain Research, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Adult, Aged, Chromosomes, Human, Pair 9, Constipation, Europe, Female, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Genotype, Humans, Irritable Bowel Syndrome, Male, Menarche, Middle Aged, Polymorphism, Single Nucleotide, Self Report, Sex Factors, Sweden, United States, SNP, Biobank Research, Bowel Symptoms, Clinical Sciences, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology

الوصف: Background & aimsGenetic factors are believed to affect risk for irritable bowel syndrome (IBS), but there have been no sufficiently powered and adequately sized studies. To identify DNA variants associated with IBS risk, we performed a genome-wide association study (GWAS) of the large UK Biobank population-based cohort, which includes genotype and health data from 500,000 participants.MethodsWe studied 7,287,191 high-quality single nucleotide polymorphisms in individuals who self-reported a doctor's diagnosis of IBS (cases; n = 9576) compared to the remainder of the cohort (controls; n = 336,499) (mean age of study subjects, 40-69 years). Genome-wide significant findings were further investigated in 2045 patients with IBS from tertiary centers and 7955 population controls from Europe and the United States, and a small general population sample from Sweden (n = 249). Functional annotation of GWAS results was carried out by integrating data from multiple biorepositories to obtain biological insights from the observed associations.ResultsWe identified a genome-wide significant association on chromosome 9q31.2 (single nucleotide polymorphism rs10512344; P = 3.57 × 10-8) in a region previously linked to age at menarche, and 13 additional loci of suggestive significance (P < 5.0×10-6). Sex-stratified analyses revealed that the variants at 9q31.2 affect risk of IBS in women only (P = 4.29 × 10-10 in UK Biobank) and also associate with constipation-predominant IBS in women (P = .015 in the tertiary cohort) and harder stools in women (P = .0012 in the population-based sample). Functional annotation of the 9q31.2 locus identified 8 candidate genes, including the elongator complex protein 1 gene (ELP1 or IKBKAP), which is mutated in patients with familial dysautonomia.ConclusionsIn a sufficiently powered GWAS of IBS, we associated variants at the locus 9q31.2 with risk of IBS in women. This observation may provide additional rationale for investigating the role of sex hormones and autonomic dysfunction in IBS.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/625706n2Test

المؤلفون: Sentís, Alexis, Kislaya, Irina, Nicolay, Nathalie, Meijerink, Hinta, Starrfelt, Jostein, Martínez-Baz, Iván, Castilla Catalán, Jesús, Nielsen, Katrine Finderup, Hansen, Christian Holm, Emborg, Hanne-Dorthe, Nardone, Anthony, Derrough, Tarik, Valenciano, Marta, Nunes, Baltazar, Monge, Susana, VEBIS-Lot4 working group, Larrauri, Amparo, Mazagatos, Clara

المساهمون: Unión Europea. European Centre for Disease Prevention and Control (ECDC)

مصطلحات موضوعية: COVID-19, Delta variant, Omicron variant, Vaccination booster dose, Vaccination primary course, Vaccine effectiveness, COVID-19 Vaccines, Aged, Electronics, Hospitalization, Humans, Pilot Projects, Registries, Vaccine Efficacy

الوصف: By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant. ; All the organisations involved have received funding from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104). ; Sí

العلاقة: Euro Surveill. 2022 Jul;27(30):2200551.; http://hdl.handle.net/20.500.12105/15461Test; Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

الإتاحة: https://doi.org/20.500.12105/15461Test
https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551Test
https://hdl.handle.net/20.500.12105/15461Test

المؤلفون: Chappell E., Turkova A., Goetghebuer T., Jackson C., Chiappini E., Galli L., Gingaras C., Judd A., Spoulou V., Lisi C., Ansone S., Wolfs T., Marczynska M., Ene L., Plotnikova Y., Voronin E., Samarina A., Jourdain G., Ngo-Giang-Huong N., Fortuny C., Navarro M. L., Ramos J. T., Naver L., Crisinel P. -A., Bailey H., Malyuta R., Volokha A., Bamford A., Crichton S., Foster C., Thorne C., Collins I. J., Giaquinto C., Gibb D. M., Critchton S., Duff C., Goodall R., Gomezpena D., Lundin R., Mangiarini L., Milanzi E., Nardone A., Hainaut M., Van der Kelen E., Delforge M., de Martino M., Tovo P. A., Gabiano C., Carloni I., Larovere D., Baldi F., Miniaci A., Pession A., Badolato R., Panto G., Anastasio E., Montagnani C., Venturini E., Bianchi L., Allodi A., Di Biagio A., Grignolo S., Giacomet V., Marchisio P., Banderali G., Tagliabue C., Cellini M., Bruzzese E., Di Costanzo P., Lo Vecchio A., Dona D., Rampon O., Romano A., Dodi I., Esposito S., Zuccaro V., Zanaboni D., Consolini R., Bernardi S., Genovese O., Cristiano L., Mazza A., Garazzino S., Mignone F., Silvestro E., Portelli V., Pajkrt D., Scherpbier H. J., Weijsenfeld A. M., de Boer C. G., Jurriaans S., Back N. K. T., Zaaijer H. L., Berkhout B., Cornelissen M. T. E., Schinkel C. J., Wolthers K. C., Fraaij P. L. A., van Rossum A. M. C., Vermont C. L., van der Knaap L. C., Visser E. G., Boucher C. A. B., Koopmans M. P. G., van Kampen J. J. A., Pas S. D., Henriet S. S. V., van de Flier M., van Aerde K., Strik-Albers R., Rahamat-Langendoen J., Stelma F. F., Scholvinck E. H., de Groot-De Jonge H., Niesters H. G. M., van Leer-Buter C. C., Knoester M., Bont L. J., Geelen S. P. M., Wolfs T. F. W., Nauta N., Schuurman R., Verduyn-Lunel F., Wensing A. M. J., Reiss P., Zaheri S., Bezemer D. O., van Sighem A. I., Smit C., Wit F. W. M. N., Hillebregt M., de Jong A., Woudstra T., Bergsma D., Grivell S., Meijering R., Raethke M., Rutkens T., de Groot L., van den Akker M., Bakker Y., Bezemer M., El Berkaoui A., Geerlinks J., Koops J., Kruijne E., Lodewijk C., Lucas E., van der Meer R., Munjishvili L., Paling F., Peeck B., Ree C., Regtop R., Ruijs Y., van de Sande L., Schoorl M., Schnorr P., Tuijn E., Veenenberg L., van der Vliet S., Wisse A., Witte E. C., Tuk B., Popielska J., Pokorska-Spiewak M., Oldakowska A., Zawadka K., Coupland U., Doroba M., Miloenko M., Labutina S., Soler-Palacin P., Frick M. A., Perez-Hoyos S., Mur A., Lopez N., Mendez M., Mayol L., Vallmanya T., Calavia O., Garcia L., Coll M., Pineda V., Rius N., Rovira N., Duenas J., Noguera-Julian A., Mellado M. J., Escosa L., Hortelano M. G., Sainz T., Gonzalez-Tome M. I., Rojo P., Blazquez D., Prieto L., Guillen S., Saavedra J., Santos M., Munoz M. A., Ruiz B., Fernandez C., Phee M., de Ory S. J., Alvarez S., Roa M. A., Beceiro J., Martinez J., Badillo K., Apilanez M., Pocheville I., Garrote E., Colino E., Sirvent J. G., Garzon M., Roman V., Montesdeoca A., Mateo M., Munoz M. J., Angulo R., Neth O., Falcon L., Terol P., Santos J. L., Moreno D., Lendinez F., Grande A., Romero F. J., Perez C., Lillo M., Losada B., Herranz M., Bustillo M., Guerrero C., Collado P., Couceiro J. A., Perez A., Piqueras A. I., Breton R., Segarra I., Gavilan C., Jareno E., Montesinos E., Dapena M., Alvarez C., Andres A. G., Marugan V., Ochoa C., Alfayate S., Menasalvas A. I., de Miguel E., Soeria-Atmadja S., Belfrage E., Hagas V., Aebi-Popp K., Anagnostopoulos A., Asner S., Battegay M., Baumann M., Bernasconi E., Boni J., Braun D. L., Bucher H. C., Calmy A., Cavassini M., Ciuffi A., Duppenthaler A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Francini K., Furrer H., Fux C. A., Grawe C., Gunthard H. F., Haerry D., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Huber M., Kahlert C. R., Kaiser L., Keiser O., Klimkait T., Kottanattu L., Kouyos R. D., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Marzolini C., Metzner K. J., Muller N., Nicca D., Paioni P., Pantaleo G., Perreau M., Polli Ch., Rauch A., Rudin C., Scherrer A. U., Schmid P., Speck R., Stockle M., Tarr P., Thanh Lecompte M., Trkola A., Vernazza P., Wagner N., Wandeler G., Weber R., Wyler C. A., Yerly S., Wannarit P., Techakunakorn P., Hansudewechakul R., Wanchaitanawong V., Theansavettrakul S., Nanta S., Ngampiyaskul C., Phanomcheong S., Hongsiriwon S., Karnchanamayul W., Kwanchaipanich R., Kanjanavanit S., Kamonpakorn N., Nantarukchaikul M., Layangool P., Mekmullica J., Lucksanapisitkul P., Watanayothin S., Lertpienthum N., Warachit B., Hanpinitsak S., Potchalongsin S., Thanasiri P., Krikajornkitti S., Attavinijtrakarn P., Srirojana S., Bunjongpak S., Puangsombat A., Na-Rajsima S., Ananpatharachai P., Akarathum N., Lawtongkum W., Kheunjan P., Suriyaboon T., Saipanya A., Than-In-At K., Jaisieng N., Suaysod R., Chailoet S., Naratee N., Kawilapat S., Kaleeva T., Baryshnikova Y., Soloha S., Bashkatova N., Raus I., Glutshenko O., Ruban Z., Prymak N., Kiseleva G., Lyall H., Butler K., Doerholt K., Doherty C., Harrison I., Kenny J., Klein N., Letting G., McMaster P., Murau F., Nsangi E., Prime K., Riordan A., Shackley F., Shingadia D., Storey S., Tudor-Williams G., Welch S., Cook C., Dobson D., Fairbrother K., Le Prevost M., Van Looy N., Peters H., Francis K., Thrasyvoulou L., Fidler K., Bernatoniene J., Manyika F., Sharpe G., Subramaniam B., Hague R., Price V., Flynn J., Cardoso A., Abou-Rayyah M., Yeadon S., Segal S., Hawkins S., Dowie M., Bandi S., Percival E., Eisenhut M., Duncan K., Anguvaa L., Wren L., Flood T., Pickering A., Murphy C., Daniels J., Lees Y., Thompson F., Williams A., Williams B., Pope S., Libeschutz S., Cliffe L., Southall S., Freeman A., Freeman H., Christie S., Gordon A., Hague D. R., Clarke L., Jones L., Brown L., Greenberg M., Benson C., Ibberson L., Patel S., Hancock J., Sharland M., Lyall E. G. H., Seery P., Kirkhope N., Raghunanan S., Callaghan A., Bridgwood A., Evans J., Blake E., Yannoulias A.

المساهمون: Chappell E., Turkova A., Goetghebuer T., Jackson C., Chiappini E., Galli L., Gingaras C., Judd A., Spoulou V., Lisi C., Ansone S., Wolfs T., Marczynska M., Ene L., Plotnikova Y., Voronin E., Samarina A., Jourdain G., Ngo-Giang-Huong N., Fortuny C., Navarro M.L., Ramos J.T., Naver L., Crisinel P.-A., Bailey H., Malyuta R., Volokha A., Bamford A., Crichton S., Foster C., Thorne C., Collins I.J., Giaquinto C., Gibb D.M., Critchton S., Duff C., Goodall R., Gomezpena D., Lundin R., Mangiarini L., Milanzi E., Nardone A., Hainaut M., Van der Kelen E., Delforge M., de Martino M., Tovo P.A., Gabiano C., Carloni I., Larovere D., Baldi F., Miniaci A., Pession A., Badolato R., Panto G., Anastasio E., Montagnani C., Venturini E., Bianchi L., Allodi A., Di Biagio A., Grignolo S., Giacomet V., Marchisio P., Banderali G., Tagliabue C., Cellini M., Bruzzese E., Di Costanzo P., Lo Vecchio A., Dona D., Rampon O., Romano A., Dodi I., Esposito S., Zuccaro V., Zanaboni D., Consolini R., Bernardi S., Genovese O., Cristiano L., Mazza A., Garazzino S., Mignone F., Silvestro E., Portelli V., Pajkrt D., Scherpbier H.J., Weijsenfeld A.M., de Boer C.G., Jurriaans S., Back N.K.T., Zaaijer H.L., Berkhout B., Cornelissen M.T.E., Schinkel C.J., Wolthers K.C., Fraaij P.L.A., van Rossum A.M.C., Vermont C.L.

مصطلحات موضوعية: Adolescent, Adult, Aged, Child, Europe, Eastern, Human, Infant, Newborn, Male, Thailand, Acquired Immunodeficiency Syndrome, HIV Infection, Neoplasms

الوصف: Investigate trends over time and predictors of malignancies among children and young people with HIV.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34049355; volume:35; issue:12; firstpage:1973; lastpage:1985; numberofpages:13; journal:AIDS; http://hdl.handle.net/2318/1870185Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115442760

الإتاحة: https://doi.org/10.1097/QAD.0000000000002965Test
http://hdl.handle.net/2318/1870185Test

المؤلفون: Eijsbouts C., Zheng T., Kennedy N. A., Bonfiglio F., Anderson C. A., Moutsianas L., Holliday J., Shi J., Shringarpure S., Agee M., Aslibekyan S., Auton A., Bell R. K., Bryc K., Clark S. K., Elson S. L., Fletez-Brant K., Fontanillas P., Furlotte N. A., Gandhi P. M., Heilbron K., Hicks B., Hinds D. A., Huber K. E., Jewett E. M., Jiang Y., Kleinman A., Lin K. -H., Litterman N. K., Luff M. K., McCreight J. C., McIntyre M. H., McManus K. F., Mountain J. L., Mozaffari S. V., Nandakumar P., Noblin E. S., Northover C. A. M., O'Connell J., Petrakovitz A. A., Pitts S. J., Poznik G. D., Sathirapongsasuti J. F., Shastri A. J., Shelton J. F., Tian C., Tung J. Y., Tunney R. J., Vacic V., Wang X., Zare A. S., Voda A. -I., Kashyap P., Chang L., Mayer E., Heitkemper M., Sayuk G. S., Ringel-Kulka T., Ringel Y., Chey W. D., Eswaran S., Merchant J. L., Shulman R. J., Bujanda L., Garcia-Etxebarria K., Dlugosz A., Lindberg G., Schmidt P. T., Karling P., Ohlsson B., Walter S., Faresjo A. O., Simren M., Halfvarson J., Portincasa P., Barbara G., Usai-Satta P., Neri M., Nardone G., Cuomo R., Galeazzi F., Bellini M., Latiano A., Houghton L., Jonkers D., Kurilshikov A., Weersma R. K., Netea M., Tesarz J., Gauss A., Goebel-Stengel M., Andresen V., Frieling T., Pehl C., Schaefert R., Niesler B., Lieb W., Hanevik K., Langeland N., Wensaas K. -A., Litleskare S., Gabrielsen M. E., Thomas L., Thijs V., Lemmens R., Van Oudenhove L., Wouters M., Farrugia G., Franke A., Hubenthal M., Abecasis G., Zawistowski M., Skogholt A. H., Ness-Jensen E., Hveem K., Esko T., Teder-Laving M., Zhernakova A., Camilleri M., Boeckxstaens G., Whorwell P. J., Spiller R., McVean G., D'Amato M., Jostins L., Parkes M.

المساهمون: Eijsbouts C., Zheng T., Kennedy N.A., Bonfiglio F., Anderson C.A., Moutsianas L., Holliday J., Shi J., Shringarpure S., Agee M., Aslibekyan S., Auton A., Bell R.K., Bryc K., Clark S.K., Elson S.L., Fletez-Brant K., Fontanillas P., Furlotte N.A., Gandhi P.M., Heilbron K., Hicks B., Hinds D.A., Huber K.E., Jewett E.M., Jiang Y., Kleinman A., Lin K.-H., Litterman N.K., Luff M.K., McCreight J.C., McIntyre M.H., McManus K.F., Mountain J.L., Mozaffari S.V., Nandakumar P., Noblin E.S., Northover C.A.M., O'Connell J., Petrakovitz A.A., Pitts S.J., Poznik G.D., Sathirapongsasuti J.F., Shastri A.J., Shelton J.F., Tian C., Tung J.Y., Tunney R.J., Vacic V., Wang X., Zare A.S., Voda A.-I., Kashyap P., Chang L., Mayer E., Heitkemper M., Sayuk G.S., Ringel-Kulka T., Ringel Y., Chey W.D., Eswaran S., Merchant J.L., Shulman R.J., Bujanda L., Garcia-Etxebarria K., Dlugosz A., Lindberg G., Schmidt P.T., Karling P., Ohlsson B., Walter S., Faresjo A.O., Simren M., Halfvarson J., Portincasa P., Barbara G., Usai-Satta P., Neri M., Nardone G., Cuomo R., Galeazzi F., Bellini M., Latiano A., Houghton L., Jonkers D., Kurilshikov A., Weersma R.K., Netea M., Tesarz J., Gauss A., Goebel-Stengel M., Andresen V., Frieling T., Pehl C., Schaefert R., Niesler B., Lieb W., Hanevik K., Langeland N., Wensaas K.-A.

مصطلحات موضوعية: Aged, Anxiety Disorder, CD56 Antigen, Cell Adhesion Molecule, Cytoskeletal Protein, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Guanine Nucleotide Exchange Factor, Homeodomain Protein, Human, Irritable Bowel Syndrome, Male, Middle Aged, Molecular Chaperone, Mood Disorder, Polymorphism, Single Nucleotide, United Kingdom

الوصف: Irritable bowel syndrome (IBS) results from disordered brain–gut interactions. Identifying susceptibility genes could highlight the underlying pathophysiological mechanisms. We designed a digestive health questionnaire for UK Biobank and combined identified cases with IBS with independent cohorts. We conducted a genome-wide association study with 53,400 cases and 433,201 controls and replicated significant associations in a 23andMe panel (205,252 cases and 1,384,055 controls). Our study identified and confirmed six genetic susceptibility loci for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6. The first four are associated with mood and anxiety disorders, expressed in the nervous system, or both. Mirroring this, we also found strong genome-wide correlation between the risk of IBS and anxiety, neuroticism and depression (rg > 0.5). Additional analyses suggested this arises due to shared pathogenic pathways rather than, for example, anxiety causing abdominal symptoms. Implicated mechanisms require further exploration to help understand the altered brain–gut interactions underlying IBS.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34741163; info:eu-repo/semantics/altIdentifier/wos/WOS:000718829500001; volume:53; issue:11; firstpage:1543; lastpage:1552; numberofpages:10; journal:NATURE GENETICS; https://hdl.handle.net/11585/856276Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118838667; https://www.nature.com/articles/s41588-021-00950-8Test

الإتاحة: https://doi.org/10.1038/s41588-021-00950-8Test
https://hdl.handle.net/11585/856276Test
https://www.nature.com/articles/s41588-021-00950-8Test

المؤلفون: Marcellusi A., Rotundo M. A., Nardone C., Sciattella P., Gazzillo S., Rossini M., Barbagallo M., Antenori A., Valle D., Mennini F. S.

المساهمون: Marcellusi, A., Rotundo, M. A., Nardone, C., Sciattella, P., Gazzillo, S., Rossini, M., Barbagallo, M., Antenori, A., Valle, D., Mennini, F. S.

مصطلحات موضوعية: Aged, Female, Health Care Cost, Hospitalization, Human, International Classification of Disease, Italy, Male, Middle Aged, Osteoporosi, Patient Discharge, State Medicine, Cost of Illness

الوصف: Background and Objective: Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs. Methods: A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were calculated considering the administrative database of the hospital discharge records for the period 2008–2016. Patients were enrolled in the analysis if they report the subsequent inclusion criteria: age ≥ 45years and presence of osteoporosis in primary or secondary diagnosis (ICD9-CM 733.0) and/or presence of a major fracture in primary or secondary diagnosis (excluding road accidents) in the following locations: spine (codes ICD9-CM: 805;806), femur (codes ICD9-CM: 820; 821), radius and ulna (codes ICD9-CM: 813.4; 813.5), humerus (codes ICD9-CM: 812.0–812.5), pelvis (code ICD9-CM: 808), tibia and fibula (codes ICD9-CM: 823), ankle (code ICD9: 824) and ribs (codes ICD9-CM: 807.0; 807.1). Costs were estimated considering the diagnosis-related group (DRG) national tariff associated with each hospitalisation. Finally, the administrative databases of the Italian National Social Security Institute (INPS) (2009–2015) were analysed for the estimate the pension and disability costs from the social perspective. Results: The model estimated an average annual economic burden of osteoporosis in Italy of €2.2 billion. Of this cost, approximately 80% (€1.8 billion) was associated with hospitalisations, 16% (€351 million) for pharmacological treatments, 3% (€71 million) for ambulatory visits, and 0.6% (€13 million) for social security ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32248346; info:eu-repo/semantics/altIdentifier/wos/WOS:000523408200001; volume:40; issue:5; firstpage:449; lastpage:458; numberofpages:10; journal:CLINICAL DRUG INVESTIGATION; http://hdl.handle.net/11573/1609142Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85083853004

الإتاحة: https://doi.org/10.1007/s40261-020-00904-8Test
http://hdl.handle.net/11573/1609142Test

المؤلفون: Homayounfar, Gelareh, Nardone, Natalie, Borkar, Durga S, Tham, Vivien M, Porco, Travis C, Enanoria, Wayne TA, Parker, John V, Vinoya, Aleli C, Uchida, Aileen, Acharya, Nisha R

المصدر: American Journal of Ophthalmology. 156(4)

مصطلحات موضوعية: Clinical Research, Prevention, Adolescent, Adult, Age Distribution, Aged, Child, Child, Preschool, Cohort Studies, Databases, Factual, Ethnicity, Female, Hawaii, Health Maintenance Organizations, Humans, Incidence, Infant, Male, Middle Aged, Retrospective Studies, Scleritis, Sex Distribution, Young Adult, Ethnic Groups, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry

الوصف: PurposeTo ascertain the incidence of scleritis and episcleritis in a Hawaiian population and describe variations by age, sex, and race.DesignRetrospective, population-based cohort study.MethodsAll electronic medical records for enrollees in Kaiser Permanente Hawaii (n = 217,061) from January 1, 2006 to December 31, 2007 were searched for International Classification of Diseases, 9th Edition (ICD-9) codes associated with ocular inflammation. Chart review was conducted to verify a clinical diagnosis of scleritis or episcleritis. Confirmed cases were used to calculate incidence rates per 100,000 person-years. Ninety-five percent confidence intervals (CI) were calculated for each incidence rate, including age-, sex-, and race-specific rates, using bias-corrected Poisson regression. To assess for confounding, a multivariate analysis adjusting for age, sex, and race was also performed.ResultsOf 217,061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100,000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Pacific Islanders were the most underrepresented racial group among cases of scleritis and episcleritis (P = .006, P = .001). Blacks had the highest incidence of scleritis (P = .004).ConclusionsThese results provide a population-based estimate of the incidence of scleritis and episcleritis in a diverse population and highlight differences in patients' demographic characteristics. Differences in incidence by sex and race raise questions about genetic and environmental influences on the development of these conditions.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/9kt1534dTest

المؤلفون: Eijsbouts, Chris, Zheng, Tenghao, Kennedy, Nicholas A., Bonfiglio, Ferdinando, Anderson, Carl A., Moutsianas, Loukas, Holliday, Joanne, Shi, Jingchunzi, Shringarpure, Suyash, Voda, Alexandru-Ioan, Farrugia, Gianrico, Franke, Andre, H��benthal, Matthias, Abecasis, Gon��alo, Zawistowski, Matthew, Skogholt, Anne Heidi, Ness-Jensen, Eivind, Hveem, Kristian, Esko, T��nu, Teder-Laving, Maris, Zhernakova, Alexandra, Camilleri, Michael, Boeckxstaens, Guy, Whorwell, Peter J., Spiller, Robin, McVean, Gil, D���Amato, Mauro, Jostins, Luke, Parkes, Miles, Agee, Michelle, Aslibekyan, Stella, Auton, Adam, Bell, Robert K., Bryc, Katarzyna, Clark, Sarah K., Elson, Sarah L., Fletez-Brant, Kipper, Fontanillas, Pierre, Furlotte, Nicholas A., Gandhi, Pooja M., Heilbron, Karl, Hicks, Barry, Hinds, David A., Huber, Karen E., Jewett, Ethan M., Jiang, Yunxuan, Kleinman, Aaron, Lin, Keng-Han, Litterman, Nadia K., Luff, Marie K., McCreight, Jey C., McIntyre, Matthew H., McManus, Kimberly F., Mountain, Joanna L., Mozaffari, Sahar V., Nandakumar, Priyanka, Noblin, Elizabeth S., Northover, Carrie A. M., O���Connell, Jared, Petrakovitz, Aaron A., Pitts, Steven J., Poznik, G. David, Sathirapongsasuti, J. Fah, Shastri, Anjali J., Shelton, Janie F., Tian, Chao, Tung, Joyce Y., Tunney, Robert J., Vacic, Vladimir, Wang, Xin, Zare, Amir S., Kashyap, Purna, Chang, Lin, Mayer, Emeran, Heitkemper, Margaret, Sayuk, Gregory S., Ringel-Kulka, Tamar, Ringel, Yehuda, Chey, William D., Eswaran, Shanti, Merchant, Juanita L., Shulman, Robert J., Bujanda, Luis, Garcia-Etxebarria, Koldo, Dlugosz, Aldona, Lindberg, Greger, Schmidt, Peter T., Karling, Pontus, Ohlsson, Bodil, Walter, Susanna, Faresj��, ��shild O., Simren, Magnus, Halfvarson, Jonas, Portincasa, Piero, Barbara, Giovanni, Usai-Satta, Paolo, Neri, Matteo, Nardone, Gerardo, Cuomo, Rosario, Galeazzi, Francesca, Bellini, Massimo, Latiano, Anna, Houghton, Lesley, Jonkers, Daisy, Kurilshikov, Alexander, Weersma, Rinse K., Netea, Mihai, Tesarz, Jonas, Gauss, Annika, Goebel-Stengel, Miriam, Andresen, Viola, Frieling, Thomas, Pehl, Christian, Schaefert, Rainer, Niesler, Beate, Lieb, Wolfgang, Hanevik, Kurt, Langeland, Nina, Wensaas, Knut-Arne, Litleskare, Sverre, Gabrielsen, Maiken E., Thomas, Laurent, Thijs, Vincent, Lemmens, Robin, Van Oudenhove, Lukas, Wouters, Mira

المساهمون: Eijsbouts C., Zheng T., Kennedy N.A., Bonfiglio F., Anderson C.A., Moutsianas L., Holliday J., Shi J., Shringarpure S., Agee M., Aslibekyan S., Auton A., Bell R.K., Bryc K., Clark S.K., Elson S.L., Fletez-Brant K., Fontanillas P., Furlotte N.A., Gandhi P.M., Heilbron K., Hicks B., Hinds D.A., Huber K.E., Jewett E.M., Jiang Y., Kleinman A., Lin K.-H., Litterman N.K., Luff M.K., McCreight J.C., McIntyre M.H., McManus K.F., Mountain J.L., Mozaffari S.V., Nandakumar P., Noblin E.S., Northover C.A.M., O'Connell J., Petrakovitz A.A., Pitts S.J., Poznik G.D., Sathirapongsasuti J.F., Shastri A.J., Shelton J.F., Tian C., Tung J.Y., Tunney R.J., Vacic V., Wang X., Zare A.S., Voda A.-I., Kashyap P., Chang L., Mayer E., Heitkemper M., Sayuk G.S., Ringel-Kulka T., Ringel Y., Chey W.D., Eswaran S., Merchant J.L., Shulman R.J., Bujanda L., Garcia-Etxebarria K., Dlugosz A., Lindberg G., Schmidt P.T., Karling P., Ohlsson B., Walter S., Faresjo A.O., Simren M., Halfvarson J., Portincasa P., Barbara G., Usai-Satta P., Neri M., Nardone G., Cuomo R., Galeazzi F., Bellini M., Latiano A., Houghton L., Jonkers D., Kurilshikov A., Weersma R.K., Netea M., Tesarz J., Gauss A., Goebel-Stengel M., Andresen V., Frieling T., Pehl C., Schaefert R., Niesler B., Lieb W., Hanevik K., Langeland N., Wensaas K.-A., Litleskare S., Gabrielsen M.E., Thomas L., Thijs V., Lemmens R., Van Oudenhove L., Wouters M., Farrugia G., Franke A., Hubenthal M., Abecasis G., Zawistowski M., Skogholt A.H., Ness-Jensen E., Hveem K., Esko T., Teder-Laving M., Zhernakova A., Camilleri M., Boeckxstaens G., Whorwell P.J., Spiller R., McVean G., D'Amato M., Jostins L., Parkes M., Eijsbouts, Chris [0000-0001-5179-0653], Anderson, Carl A. [0000-0003-1719-7009], Moutsianas, Loukas [0000-0001-5453-345X], Holliday, Joanne [0000-0003-4568-7320], Shringarpure, Suyash [0000-0001-6464-2668], Voda, Alexandru-Ioan [0000-0003-2974-6992], Farrugia, Gianrico [0000-0003-3473-5235], Hübenthal, Matthias [0000-0002-5956-3006], Abecasis, Gonçalo [0000-0003-1509-1825], Zawistowski, Matthew [0000-0002-3005-083X], Ness-Jensen, Eivind [0000-0001-6005-0729], Teder-Laving, Maris [0000-0002-5872-1850], Camilleri, Michael [0000-0001-6472-7514], Whorwell, Peter J. [0000-0002-5220-8474], Spiller, Robin [0000-0001-6371-4500], McVean, Gil [0000-0002-5012-4162], D’Amato, Mauro [0000-0003-2743-5197], Jostins, Luke [0000-0002-2475-3969], Parkes, Miles [0000-0002-6467-0631], Apollo - University of Cambridge Repository, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Eijsbouts, C., Zheng, T., Kennedy, N. A., Bonfiglio, F., Anderson, C. A., Moutsianas, L., Holliday, J., Shi, J., Shringarpure, S., Agee, M., Aslibekyan, S., Auton, A., Bell, R. K., Bryc, K., Clark, S. K., Elson, S. L., Fletez-Brant, K., Fontanillas, P., Furlotte, N. A., Gandhi, P. M., Heilbron, K., Hicks, B., Hinds, D. A., Huber, K. E., Jewett, E. M., Jiang, Y., Kleinman, A., Lin, K. -H., Litterman, N. K., Luff, M. K., Mccreight, J. C., Mcintyre, M. H., Mcmanus, K. F., Mountain, J. L., Mozaffari, S. V., Nandakumar, P., Noblin, E. S., Northover, C. A. M., O'Connell, J., Petrakovitz, A. A., Pitts, S. J., Poznik, G. D., Sathirapongsasuti, J. F., Shastri, A. J., Shelton, J. F., Tian, C., Tung, J. Y., Tunney, R. J., Vacic, V., Wang, X., Zare, A. S., Voda, A. -I., Kashyap, P., Chang, L., Mayer, E., Heitkemper, M., Sayuk, G. S., Ringel-Kulka, T., Ringel, Y., Chey, W. D., Eswaran, S., Merchant, J. L., Shulman, R. J., Bujanda, L., Garcia-Etxebarria, K., Dlugosz, A., Lindberg, G., Schmidt, P. T., Karling, P., Ohlsson, B., Walter, S., Faresjo, A. O., Simren, M., Halfvarson, J., Portincasa, P., Barbara, G., Usai-Satta, P., Neri, M., Nardone, G., Cuomo, R., Galeazzi, F., Bellini, M., Latiano, A., Houghton, L., Jonkers, D., Kurilshikov, A., Weersma, R. K., Netea, M., Tesarz, J., Gauss, A., Goebel-Stengel, M., Andresen, V., Frieling, T., Pehl, C., Schaefert, R., Niesler, B., Lieb, W., Hanevik, K., Langeland, N., Wensaas, K. -A., Litleskare, S., Gabrielsen, M. E., Thomas, L., Thijs, V., Lemmens, R., Van Oudenhove, L., Wouters, M., Farrugia, G., Franke, A., Hubenthal, M., Abecasis, G., Zawistowski, M., Skogholt, A. H., Ness-Jensen, E., Hveem, K., Esko, T., Teder-Laving, M., Zhernakova, A., Camilleri, M., Boeckxstaens, G., Whorwell, P. J., Spiller, R., Mcvean, G., D'Amato, M., Jostins, L., Parkes, M.

المصدر: Nature Genetics
Nature genetics, 53(11), 1543-1552. Nature Publishing Group

مصطلحات موضوعية: Male, Molecular Chaperone, Mood Disorder, 631/208/205/2138, Biology, 692/699/1503/1502/2071, Bioinformatics, Polymorphism, Single Nucleotide, Genetic pathways, 38/43, Irritable Bowel Syndrome, Cytoskeletal Protein, Genetics, medicine, Genetic predisposition, Aged, Anxiety Disorders, CD56 Antigen, Cell Adhesion Molecules, Cytoskeletal Proteins, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Guanine Nucleotide Exchange Factors, Homeodomain Proteins, Humans, Middle Aged, Molecular Chaperones, Mood Disorders, United Kingdom, Polymorphism, 692/699/476, Irritable bowel syndrome, Depression (differential diagnoses), article, Homeodomain Protein, Single Nucleotide, Guanine Nucleotide Exchange Factor, medicine.disease, Neuroticism, Biobank, Mood, Cell Adhesion Molecule, Anxiety, medicine.symptom, Anxiety Disorder, Human

الوصف: Funder: Kennedy Trust Rheumatology Research Prize Studentship
Funder: DFG Cluster of Excellence ���Precision Medicine in Chronic In-flammation��� (PMI; ID: EXC2167)
Funder: EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: ���Ideas��� Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013)); doi: https://doi.org/10.13039/100011199Test; Grant(s): 715772
Funder: NWO-VIDI grant 016.178.056, the Netherlands Heart Foundation CVON grant 2018-27, and NWO Gravitation grant ExposomeNL
Funder: Li Ka Shing Foundation (Li Ka Shing Foundation Limited); doi: https://doi.org/10.13039/100007421Test
Irritable bowel syndrome (IBS) results from disordered brain���gut interactions. Identifying susceptibility genes could highlight the underlying pathophysiological mechanisms. We designed a digestive health questionnaire for UK Biobank and combined identified cases with IBS with independent cohorts. We conducted a genome-wide association study with 53,400 cases and 433,201 controls and replicated significant associations in a 23andMe panel (205,252 cases and 1,384,055 controls). Our study identified and confirmed six genetic susceptibility loci for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6. The first four are associated with mood and anxiety disorders, expressed in the nervous system, or both. Mirroring this, we also found strong genome-wide correlation between the risk of IBS and anxiety, neuroticism and depression (rg > 0.5). Additional analyses suggested this arises due to shared pathogenic pathways rather than, for example, anxiety causing abdominal symptoms. Implicated mechanisms require further exploration to help understand the altered brain���gut interactions underlying IBS.

وصف الملف: application/pdf; ELETTRONICO; application/zip; text/xml

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d3e63ecdfa51d27cd4c008b5d1360dTest
https://doi.org/10.1038/s41588-021-00950-8Test

المؤلفون: Sormani M. P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., Radaelli M., Immovilli P., Capobianco M., Trojano M., Zaratin P., Tedeschi G., Comi G., Battaglia M. A., Patti F., Salvetti M., Nozzolillo A., Bellacosa A., Protti A., Di Sapio A., Signori A., Petrone A., Bisecco A., Iovino A., Dutto A., Repice A. M., Conte A., Bertolotto A., Bosco A., Gallo A., Zito A., Sartori A., Giometto B., Tortorella C., Antozzi C., Pozzilli C., Mancinelli C. R., Zanetta C., Cordano C., Scandellari C., Guaschino C., Gasperini C., Solaro C., Fioretti C., Bezzini D., Marastoni D., Paolicelli D., Vecchio D., Landi D., Bucciantini E., Pedrazzoli E., Signoriello E., Sbragia E., Susani E. L., Curti E., Milano E., Marinelli F., Camilli F., Boneschi F. M., Govone F., Bovis F., Calabria F., Caleri F., Rinaldi F., Vitetta F., Corea F., Crescenzo F., Teatini F., Tabiadon G., Granella F., Boffa G., Lus G., Brichetto G., Maniscalco G. T., Borriello G., De Luca G., Konrad G., Vaula G., Marfia G. A., Mallucci G., Liberatore G., Salemi G., Miele G., Sibilia G., Pesci I., Brambilla L., Lopiano L., Sinisi L., Pasquali L., Saraceno L., Chiveri L., Mancinelli L., Grimaldi L. M. E., Caniatti L. M., Cava M. D., Onofrj M., Rovaris M., Vercellino M., Bragadin M. M., Buccafusca M., Buscarinu M. C., Celani M. G., Grasso M. G., Stromillo M. L., Petracca M., Amato M. P., L'Episcopo M. R., Sessa M., Ferro M. T., Ercolani M. V., Bianco M., Re M. L., Vianello M., Clerico M., di Napoli M., Ponzano M., Conti M. Z., Calabrese M., Mirabella M., Filippi M., Inglese M., Lucchini M., Pozzato M., Danni M. C., Zaffaroni M., Zampolini M., Ponzio M., De Riz M., De Stefano N., Cavalla P., De Mitri P., Grossi P., Confalonieri P., Gallo P., Ragonese P., Sola P., Annovazzi P., Iaffaldano P., Nardone R., Cerqua R., Clerici R., Lanzillo R., Motta R., Balgera R., Bergamaschi R., Totaro R., Iodice R., Capra R., Marangoni S., Realmuto S., Cottone S., Montepietra S., Rasia S., Arena S., Bucello S., Banfi S., Bonavita S., Malucchi S., Tonietti S., Vollaro S., Cordera S., Aguglia U., Clerici V. T., Barcella V., Bergamaschi V., Morra V. B., Dattola V., Mantero V.

المساهمون: Sormani, M. P., De Rossi, N., Schiavetti, I., Carmisciano, L., Cordioli, C., Moiola, L., Radaelli, M., Immovilli, P., Capobianco, M., Trojano, M., Zaratin, P., Tedeschi, G., Comi, G., Battaglia, M. A., Patti, F., Salvetti, M., Nozzolillo, A., Bellacosa, A., Protti, A., Di Sapio, A., Signori, A., Petrone, A., Bisecco, A., Iovino, A., Dutto, A., Repice, A. M., Conte, A., Bertolotto, A., Bosco, A., Gallo, A., Zito, A., Sartori, A., Giometto, B., Tortorella, C., Antozzi, C., Pozzilli, C., Mancinelli, C. R., Zanetta, C., Cordano, C., Scandellari, C., Guaschino, C., Gasperini, C., Solaro, C., Fioretti, C., Bezzini, D., Marastoni, D., Paolicelli, D., Vecchio, D., Landi, D., Bucciantini, E., Pedrazzoli, E., Signoriello, E., Sbragia, E., Susani, E. L., Curti, E., Milano, E., Marinelli, F., Camilli, F., Boneschi, F. M., Govone, F., Bovis, F., Calabria, F., Caleri, F., Rinaldi, F., Vitetta, F., Corea, F., Crescenzo, F., Teatini, F., Tabiadon, G., Granella, F., Boffa, G., Lus, G., Brichetto, G., Maniscalco, G. T., Borriello, G., De Luca, G., Konrad, G., Vaula, G., Marfia, G. A., Mallucci, G., Liberatore, G., Salemi, G., Miele, G., Sibilia, G., Pesci, I., Brambilla, L., Lopiano, L., Sinisi, L., Pasquali, L., Saraceno, L., Chiveri, L., Mancinelli, L., Grimaldi, L. M. E., Caniatti, L. M.

مصطلحات موضوعية: Adolescent, Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized, COVID-19, Dimethyl Fumarate, Female, Fingolimod Hydrochloride, Hospitalization, Human, Immunologic Factor, Immunosuppressive Agent, Intensive Care Unit, Interferon, Male, Middle Aged, Mortality, Multiple Sclerosi, Natalizumab, SARS-CoV-2, Severity of Illness Index, Young Adult

الوصف: Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists. ANN NEUROL 2021;89:780–789.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33480077; info:eu-repo/semantics/altIdentifier/wos/WOS:000616353600001; volume:89; issue:4; firstpage:780; lastpage:789; numberofpages:10; journal:ANNALS OF NEUROLOGY; http://hdl.handle.net/11368/3021146Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100758179; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013440Test/

الإتاحة: https://doi.org/10.1002/ana.26028Test
http://hdl.handle.net/11368/3021146Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013440Test/